Free tool
FAERS Monitor: Pertzye
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 022175 or its brand name (Pertzye, Pancrelipase (Amylase, Lipase, Protease)). Reports on generic versions are filed under their own applications.
Reports
3,036
Serious
2,620
86% of reports
Hospitalization
1,759
Death reported
297
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea262
- nausea173
- dyspnoea148
- fatigue144
- infective pulmonary exacerbation of cystic fibrosis137
- off label use134
- vomiting132
- pneumonia130
- abdominal pain122
- cough120
- pyrexia120
- asthenia117
- weight decreased112
- pain101
- drug ineffective98
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 22 |
| 2005 | 16 |
| 2006 | 10 |
| 2007 | 13 |
| 2008 | 12 |
| 2009 | 21 |
| 2010 | 45 |
| 2011 | 49 |
| 2012 | 51 |
| 2013 | 65 |
| 2014 | 62 |
| 2015 | 101 |
| 2016 | 123 |
| 2017 | 121 |
| 2018 | 189 |
| 2019 | 297 |
| 2020 | 278 |
| 2021 | 259 |
| 2022 | 297 |
| 2023 | 293 |
| 2024 | 295 |
| 2025 | 277 |
| 2026 | 140 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,123 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infective pulmonary exacerbation of cystic fibrosisSignal | 137 | 178.9 | 151.5 | 23,454 |
| abdominal painSignal | 122 | 3.6 | 3.1 | 233 |
| coughSignal | 120 | 3.0 | 2.5 | 156 |
| diarrhoeaSignal | 262 | 2.8 | 2.5 | 314 |
| pneumoniaSignal | 130 | 2.8 | 2.4 | 149 |
| weight decreasedSignal | 112 | 2.8 | 2.3 | 128 |
| pyrexiaSignal | 120 | 2.4 | 2.0 | 98 |
| astheniaSignal | 117 | 2.2 | 1.8 | 73 |
| vomiting | 132 | 1.9 | 1.6 | 61 |
| dyspnoea | 148 | 1.8 | 1.5 | 54 |
| nausea | 173 | 1.5 | 1.3 | 31 |
| fatigue | 144 | 1.3 | 1.1 | 9 |
| pain | 101 | 1.1 | 0.9 | 2 |
| off label use | 134 | 1.1 | 0.9 | 0 |
| drug ineffective | 98 | 0.5 | 0.4 | 47 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.